• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Saracatinib

Product ID S0168
Cas No. 379231-04-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $41.00 In stock
5 mg $61.50 In stock
25 mg $204.50 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Saracatinib is an inhibitor of Src and Abl family kinases that is used for its anticancer chemotherapeutic and immunomodulatory benefits. Saracatinib is currently in clinical trials as a potential treatment for a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, and myeloma. In cellular and animal models, this compound inhibits migration, invasion, and growth of cancer cells. Additionally, saracatinib displays mixed immunomodulatory effects, decreasing T cell cytokine production in one in vitro model and increasing CD8+ memory T cells and production of IFN-γ in another in vitro model.

Product Info

Cas No.

379231-04-6

Purity

≥98%

Formula

C27H32ClN5O5

Formula Wt.

542.03

Chemical Name

N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine

IUPAC Name

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine

Synonym

AZD-0530

Appearance

Off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

S0168 MSDS PDF

Info Sheet

S0168 Info Sheet PDF

References

Gangadhar TC, Clark JI, Karrison T, et al. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun;31(3):769-73. PMID: 23151808.

Nam HJ, Im SA, Oh DY, et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther. 2013 Jan;12(1):16-26. PMID: 23144237.

Cavalloni G, Peraldo-Neia C, Sarotto I, et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012 Jul;11(7):1528-38. PMID: 22452946.

Takai S, Sabzevari H, Farsaci B, et al. Distinct effects of saracatinib on memory CD8+ T cell differentiation. J Immunol. 2012 May 1;188(9):4323-33. PMID: 22450814.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only